KaydedilenlerDerginizi ekleyin

Dergiler / Medicine Science / 2014 / Cilt: 3 - Sayı: 3

Comparison of Cefuroxim versus Cefotaxim in the Treatment of Pneumonia in Children Aged 3 Months- 5 Years an Imaging and Clinical Examination Evidence: Randomized Controlled Trial

Hashem Mohammed MANSOUR
Shaban Al MOBAYED
Ahmed El MANASRA
Rola S. ABUDALFA
Sayfa
1470–1478
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thereby, it should be recommended to treat pneumonia in children.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Pneumonia is a common and potentially serious infection that affects children throughout the world.
📊
Temel Bulgular & Veri:All 3 months-5 years old children admitted from 2/1/2012 to 4/31/2012 at Dorrah Hospital in Gaza were included in this study.
💡
Sonuç & Katkı:Thereby, it should be recommended to treat pneumonia in children.
🔬Tür:Araştırma Makalesi
📍Kapsam:2012 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Pneumonia is a common and potentially serious infection that affects children throughout the world. The aim of this study was to compare between cefuroxim and cefotaxim in the treatment of children with pneumonia. All 3 months-5 years old children admitted from 2/1/2012 to 4/31/2012 at Dorrah Hospital in Gaza were included in this study. The clinical outcome, length of hospital stay, and the association of pneumonia incidence to gender and age were compared. Of the 110 children admitted for non-complicated community acquired pneumonia (CAP), sixty patients were treated with cefuroxime and fifty were treated with cefotaxim. Clinical outcome and length of hospital stay is similar between both groups. Interestingly, the pneumonia incidence is higher in younger children and males. In conclusion, both drugs have similar treatment efficacy in terms of clinical outcome and the length of hospital stay. However, cefuroxim has several advantages over cefotaxim, including (1) oral form, allowing outpatient management, (2) less frequency of administration. Thereby, it should be recommended to treat pneumonia in children.

🔖

Bu Makaleye Atıf Yap

MANSOUR, H. M., MOBAYED, S. A., MANASRA, A. E., ABUDALFA, R. S. (2014). Comparison of Cefuroxim versus Cefotaxim in the Treatment of Pneumonia in Children Aged 3 Months- 5 Years an Imaging and Clinical Examination Evidence: Randomized Controlled Trial. Medicine Science, Cilt: 3 - Sayı: 3, 1470–1478. https://ajindex.com/articles/277801

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Barson WJ, Edwards MS, Mallory GB, Torkya MM. Pneumonia in children: inpatient treatment. http://www.uptodate.com/contents/pneumonia-in-children-inpatienttreatment access date 30.03.2014 2. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, Kurki S, Rönnberg PR, Seppä A, Soimakallio S. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993
  2. 137(9):977-88. 3. Bennett NJ, Joseph Domachowske J, Steele RW. Pediatric Pneumonia. http://emedicine.medscape.com/article/967822-overview access date 30.03.2014 4. Principi N, Esposito S. Mycoplasma pneumoniae and Chlamydia pneumoniae cause lower respiratory tract disease in paediatric patients. Curr Opin Infect Dis. 2002
  3. 15(3):295-300. 5. Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, Kallinen S, Stén M, Tarkiainen A, Rönnberg PR, Kleemola M, Mäkelä PH, Leinonen M. Etiology of childhood pneumonia: serologic results of a prospective, populationbased study. Pediatr Infect Dis J. 1998
  4. 17(11):986-91. 6. Ostapchuk M, Roberts DM, Haddy R. Community-acquired pneumonia in infants and children. Am Fam Physician. 2004
  5. 70(5):899-908. 7. Le Saux N, Robinson J. Pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health. 2011
  6. 16(7):417-24. 8. Cincinnati Children's Hospital Medical Center Health Policy and Clinical Effectiveness Program. Evidence based clinical practice guideline. Community acquired pneumonia in children 60 days to 17 years of age. http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9199/1633ae60- cbd1-4fbd-bba4-cb687fbb1d42.pdf access date 30.03.2014 9. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, Sewell L, Singh SJ, Walker PP, Walmsley S. British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax. 2013
  7. 68(Suppl 2):1-30. 10. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011
  8. 53(7):617-30. 11. Bradley JS. New recommendations for pediatric pneumonia treatment. http:/